


RealRate

PHARMACEUTICAL 2019



Akebia Therapeutics Inc. Rank 82 of 371





PHARMACEUTICAL 2019



Akebia Therapeutics Inc. Rank 82 of 371



The relative strengths and weaknesses of Akebia Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Akebia Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 134% points. The greatest weakness of Akebia Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 44% points.

The company's Economic Capital Ratio, given in the ranking table, is 17%, being 349% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	468,275
Cost of Goods Sold	7,768
Intangible Assets	55,053
Liabilities, Current	265,693
Liabilities, Non-Current	85,282
Other Assets	465,189
Other Compr. Net Income	181
Other Expenses	-28,271
Other Liabilities	9,637
Other Net Income	6,235
Property and Equipment	8,023
Research and Development	291,007
Revenues	207,742
Selling, General and Administrative Expense	87,061

Output Variable	Value in 1000 USD
Assets	996,540
Liabilities	360,612
Expenses	357,565
Stockholders Equity	635,928
Net Income	-143,588
Comprehensive Net Income	-143,498
Economic Capital Ratio	17%